RAG-1C achieves dual IND clearances from both U.S. FDA and China CDE, paving the way for global clinical development of the world's first saRNA therapy for ocular diseases RAG-1C utilizes Ractigen's clinically validated LiCO™ platform to target p21 gene activation for long-lasting...
Hence then, the article about ractigen therapeutics announces u s fda ind clearance for first in class sarna candidate rag 1c to treat proliferative vitreoretinopathy was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( Ractigen Therapeutics Announces U.S. FDA IND Clearance for First-in-Class saRNA Candidate RAG-1C to Treat Proliferative Vitreoretinopathy )
Also on site :
- Kaigene Enters into Exclusive Licensing Agreement with Taisho Pharmaceutical for Next-Generation Autoimmune Asset KG006 in Japan
- Andy Jassy said Amazon will spend $220 billion this year—and still won’t have enough capacity to meet demand
- MSFT Deadline: MSFT Investors Have Opportunity to Lead Microsoft Corporation Securities Fraud Lawsuit